Get the Stockscreener App
42.23
5.29%
2.12
After Hours:
42.35
0.12
+0.28%
Moderna Inc stock is traded at $42.23, with a volume of 16.32M.
It is up +5.29% in the last 24 hours and up +6.64% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$40.11
Open:
$41.85
24h Volume:
16.32M
Relative Volume:
1.42
Market Cap:
$16.50B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-4.8373
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+2.97%
1M Performance:
+6.64%
6M Performance:
+57.05%
1Y Performance:
+32.30%
1-Day Range:
$41.20
$44.80
1-Week Range:
$36.66
$45.50
52-Week Range:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
42.23 | 15.67B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot - The Cancer Letter
Barclays starts Moderna, Inc. (MRNA) neutral as biotech outlook improves - MSN
Moderna CEO Worries About Drug Development Overall After US FDA mRNA-1010 Refusal-To-File - Citeline News & Insights
Moderna looks outside US for growth after FDA’s flu shot refusal - whbl.com
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results - FinancialContent
Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend - FXEmpire
Moderna Reports a Narrower-Than-Expected Loss. The Stock Slips After Earnings. - Barron's
Moderna Has A Few Words For The FDA After mRNA-1010 Refusal-To-File - Citeline News & Insights
Moderna, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Moderna: Q4 Earnings Snapshot - theheraldreview.com
Moderna Inc (MRNA) Q4 2025 Earnings Call Highlights: Strategic Cost Reductions Amidst Financial Challenges - GuruFocus
Moderna (MRNA) Faces Challenges Amid Renewed Interest in Biotech Sector - GuruFocus
Moderna Challenges FDA After Flu Shot Review Refusal, 26% Covid Drop - GuruFocus
Market movers: Moderna, Pinterest, DraftKings, Coinbase, Immunic... - Proactive financial news
Moderna's mRNA Technology Has Potential Across Vaccines, Oncology, and Rare Diseases - Morningstar
Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results, Beats Estimates By $0.68 EPS - MarketBeat
Moderna shares jump as company affirms growth outlook - BioPharma Dive
Moderna shares pop on strong guidance, smaller-than-expected loss - Yahoo Finance
Pink Sheet Podcast: US FDA Versus Moderna And The Changing Role Of Refuse To File Actions - Citeline News & Insights
Moderna climbs 11% after Q4 revenue beats estimates - breakingthenews.net
Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates - TradingView
FDA refuses to consider Moderna flu shot in move experts claim is part of ‘anti-vaccine agenda’ - The Guardian
Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation - BioSpace
Moderna beats Q4 revenue estimate - BNN Bloomberg
Moderna (MRNA) Shares Rise Despite FDA Rejection of Flu Vaccine Application - GuruFocus
Moderna tops Q4 2025 EPS by 51c, beats on revenue - The Pharma Letter
Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms - Benzinga
Moderna (NASDAQ:MRNA) Trading 7.2% Higher Following Better-Than-Expected Earnings - MarketBeat
Moderna Maintains Full-Year Revenue Growth Outlook Following Fourth-Quarter Beat - marketscreener.com
Moderna Q4 Earnings Call Highlights - MarketBeat
Moderna Shares Rise After Q4 Loss Narrows, Revenue Beats Estimates - marketscreener.com
Softer-Than-Expected Inflation Sparks Rally In These 10 Stocks - Benzinga
Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, and More Movers - Barron's
Moderna Q4 2025 slides reveal strategic pivot as losses narrow, shares climb - Investing.com
Moderna Sales Beat as Covid Shot Demand Falls Less Than Expected - Bloomberg.com
Earnings call transcript: Moderna’s Q4 2025 results exceed expectations - Investing.com
Moderna Reiterates 10% Revenue-Growth Target as Covid Vaccine Demand Falls - The Wall Street Journal
Moderna Reiterates 10% Revenue-Growth Target as Covid Vaccine Demand Falls -- Update - marketscreener.com
Moderna Q4 Loss Narrows - Nasdaq
AI for investors - MLQ.ai
Moderna beats quarterly revenue estimates on resilient COVID shot sales - BNN Bloomberg
A Political Appointee Overruled FDA Scientists to Block Moderna's Flu Vaccine — and the Fallout Is Just Beginning - WebProNews
Applied Materials, Arista, Moderna, Coinbase, DraftKings, Steel Dynamics, Rivian, Roku, and More Movers - Barron's
Moderna Just Crushed Estimates While Everyone Was Looking the Other Way - 24/7 Wall St.
Moderna (MRNA) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Moderna (MRNA) Surpasses Q4 Earnings Expectations Despite Revenue Decline - GuruFocus
Moderna (MRNA) Q4 2025 Earnings Call Transcript - The Globe and Mail
Moderna Narrows Loss, Reiterates 10% Revenue Growth Target - The Wall Street Journal
Moderna beats quarterly revenue estimates on resilient sales of COVID shot - marketscreener.com
Moderna announces influenza vaccine filing accepted for regulatory review in the EU - marketscreener.com
Moderna (MRNA) Exceeds Revenue Estimates and Looks Ahead to Growth - GuruFocus
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):